Making Sense of Myeloma Treatment Advances
|
|
- Emmeline Baker
- 6 years ago
- Views:
Transcription
1 Making Sense of Myeloma Treatment Advances Webinar 1, May 17, 217 Updates From the 16th International Myeloma Workshop and the American Association for Cancer Research 217 Annual Meeting Speakers Moderator: Mary DeRome Multiple Myeloma Research Foundation Norwalk, Connecticut Faculty: Lawrence Boise, PhD Emory University Atlanta, Georgia Shaji Kumar, MD Mayo Clinic Rochester, Minnesota 1
2 Topics for Discussion Disease biology and risk stratification Newly diagnosed myeloma Stem cell transplantation Minimal residual disease (MRD) in myeloma Relapsed myeloma Venetoclax New immune therapies Myeloma Treatment Paradigm SCT Eligible SCT Ineligible Diagnosis & Risk Stratification Induction Consolidation Maintenance Induction followed by continuous therapy Treatment of relapsed disease Treatment-free interval? Tumor Burden SCT, stem cell transplant 2
3 Disease Biology and Risk Stratification Asymptomatic Myeloma What factors control progression? Up-front genetics? Acquired changes? Other factors? 3
4 Acquired Changes in Myeloma pre MGUS MGUS AMM MM B In this model a change to a cell with asymptomatic disease results in symptomatic myeloma. A Seckinger A et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-15. Up-Front Genetics in Myeloma pre MGUS MGUS AMM MM MGUS AMM MM B In this model the genetic changes occur earlier and other factors determine when the disease becomes symptomatic Seckinger A et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-15. 4
5 Tumor Mass, Proliferation, and Up-Front Factors Are Predictors of Progression to Symptomatic Myeloma M protein Doubling time UAMS7 gene score Seckinger A et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-15. Disease Progression: More Than One Way to Evolve Neutrally evolving Darwinian selection (Non-neutral) Johnson D et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-16. 5
6 Neutral-Evolution Disease Responds Differently to Non-Intensive Therapy Intensive Treatment Overall Survival Median not reached Non-intensive Treatment Overall Survival Median 27.3 vs months (P<.1) Johnson D et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-16. Using Next-Generation Sequencing for Myeloma Staging Standard Risk Factors for MM and the R-ISS Prognostic Factor ISS stage I II III CA by ifish High risk Standard risk LDH Normal High Criteria Serum β2m <3.5 mg/l serum albumin 3.5 g/dl Not ISS stage I or III Serum β2m 5.5 mg/l Presence of del(17p) and/or translocation t(4;14) and/or translation t(14;16) No high-risk CA Serum LDH < the upper limit of normal Serum LDH > the upper limit of normal A new model for risk stratification for MM R-ISS stage I ISS stage I and standard-risk CA by ifish and normal LDH II Not R-ISS stage I or III III ISS stage III and either high-risk CA by ifish or high LDH CA, chromosomal abnormalities; ifish, interphase fluorescent in situ hybridization; ISS, International Staging System; LDH, lactate dehydrogenase; MM, multiple myeloma; R-ISS, revised International Staging System. Fiala M et al. Presented at the 16th International Myeloma Workshop, March 1-4, 217. Abstract OP-29. Palumbo A, et al. J Clin Oncol. 215;33:
7 Using Next-Generation Sequencing for Myeloma Staging Data: Interim analysis 9 from the MMRF CoMMpass study. Controlling for Age (>65 vs 65) and Sex Fiala M et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-29. Sequencing From the Blood (or do we need to do so many bone marrows?) Circulating tumor cells (CTCs) are rare myeloma plasma cells found in the blood Circulating free DNA (cfdna) is DNA released from dead cells into the bloodstream 733 non-silent mutations cfdna 8% BM cells 1% 63% CTCs 7% Sequencing from CTCs or cfdna can provide similar results to sequencing from the bone marrow Manier S et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-4. 7
8 Making Sense of Myeloma Treatment Advances Developing New Ways to Measure Disease Current standard methods for measuring M protein in the blood or urine were developed in the 196s New antibody therapies interfere with these methods Intensity Purify Ig using Camelids +2 miramm Screen + MRD* Screen Mass (Da) +1 Release of light chain DTT Analyze on MASS-FIX Inject on microlc miramm MRD T mabs Mass reconstruction Using mass spectrometry to measure antibodies or light chains is more sensitive (MRD) and more precise (no therapeutic antibody interference). 1 X IFE ESI Intensity Intensity Analyze on 56 Q-TOF MS m/z 22,85.7 Da M-protein (mig) Polyclonal LCs Mass (Da) MFMER slide 13 Murray D et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-3. Newly Diagnosed Myeloma 8
9 SWOG S777: VRd vs Rd Eight 21-Day Cycles of VRd Randomization N=525 Stratification: ISS (I, II, III) Intent to progression (yes/no) Bortezomib 1.3/mg 2 IV Days 1, 4, 8, and 11 Lenalidomide 25 mg/day PO Days 1-14 Dexamethasone 2 mg/day PO Days 1, 2, 4, 5, 8, 9, 11, 12 Six 28-Day Cycles of Rd Lenalidomide 25 mg/day PO Days 1-21 Dexamethasone 4 mg/day PO Days 1, 8, 15, 22 Lenalidomide 25 mg/day PO Days 1-21 Dexamethasone 4 mg/day PO Days 1, 8,15, 22 ISS, International Staging System; Rd, lenalidomide + dexamethasone; SWOG, Southwest Oncology Group; VRd, bortezomib + lenalidomide + dexamethasone Durie BG et al. Lancet. 217;389:519. Response and Survival Outcomes Progression free survival Overall Survival Durie BG et al. Lancet. 217;389:519. 9
10 CLARION Study Design Randomization 1:1 N=955 Stratification: ISS stage Route of bortezomib administration (if randomized to VMP) Region Age Maximum 9 cycles KMP Carfilzomib* 36 mg/m 2 Days 1, 2, 8, 9, 22, 23, 29, 3 (2 mg/m 2 days 1, 2, cycle 1 only) IV over 3 minutes Melphalan 9 mg/m 2 and prednisone 6 mg/m 2 Days 1 4 Maximum 9 cycles VMP Bortezomib 1.3 mg/m 2 Days 1, 4, 8, 11, 22, 25, 29, 32 (Days 4, 11, 25, 32 omitted for cycles 5+) IV or SC Melphalan 9 mg/m 2 and prednisone 6 mg/m 2 Days 1 4 Primary end point: PFS Secondary end points: OS, CRR, ORR, grade 2 PN rate, HRQoL, safety and tolerability Exploratory end point: MRD *Carfilzomib was administered for 2 weeks out of 3 twice per cycle Melphalan dose was 7 mg/m 2 if age was >75 years or CrCL was 3 to <5 ml/min; 5 mg/m 2 if CrCl was 15 to <3 ml/min. Facon T et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-44. Proportion Event-Free Number at risk: KMP VMP Primary End Point: Progression-Free Survival KMP VMP Months Disease progression or death n (%) Median PFS months HR for KMP vs VMP (95% CI) Median follow-up time: 22.2 months for KMP and 21.6 months for VMP The absence of PFS difference was consistent across subgroups KMP (n=478) 27 (43.3) ( ) 1-sided P= VMP (n=477) 214 (44.9) 22.1 Facon T et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-44. 1
11 Secondary End Point: Response Rates Patients (%) Odds ratio (95% CI): 1.18 ( ) Odds ratio (95% CI): 1.65 ( ) 61.3% 49.3% Odds ratio (95% CI): 1.41 ( ) 84.3% 78.8% 25.9% 23.1% n=124 n=11 n=293 n=235 n=43 n=376 CRR ( CR) VGPR ORR ( PR) KMP VMP Median DOR: 25.2 months (95% CI, 21.3 NE) for KMP vs 22.8 months (95% CI, ) for VMP Facon T et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-44. Adverse Events Hematologic AE % KMP (n=474) VMP (n=47) All grade Grade 3 All grade Grade 3 Anemia Thrombocytopenia Neutropenia Febrile neutropenia Nonhematologic AE % ( 2% in either arm) Pyrexia Nausea Vomiting Diarrhea Constipation Peripheral neuropathy Facon T et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP
12 KMP Once-Weekly K, phase 1 Induction: 9 cycles of 35 days Carfilzomib (2 mg at D1C1 then or 7 mg/m² depending on cohort) Weekly IV (day 1,8,15,22) followed by a 13-day rest In combination with melphalan.25 mg/kg/d and prednisone 6 mg/m² by mouth on days 1 to 4 (patient diary) 13 days rest κ κ κ κ J1 J2 J3 J4 MP J8 Maintenance: J15 J22 Cycle 1 of 35 days Cycle 2 13 cycles of 28 days. Carfilzomib: 36 mg/m² twice a month (day 1 and 15) IV for 1 year MP, melphalan prednisone; κ, carfilzomib Leleu X et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-12. KMP With Weekly K The MTD of K will be at 7 mg/m 2 up to 75 years old, and 56 above The CR rate of KMP weekly is remarkable, possibly greater than previous reports of VMP and KMP (twice a week 36) Study Schema Design PI ORR, % CR, % IFM KMP Weekly C Carmysap 1 KMP Bi-Weekly 9 12 Vista 2 VMP Bi-Weekly Mateos 3 VMP Weekly C2 8 Palumbo 4 VMP VMPT-VT Weekly C (39 end maintenance) Moreau P et al. Blood. 215;125: San Miguel J et al. N Engl J Med. 28;359: Mateos MV et al. Lancet Oncol. 21;11: Palumbo A et al. J Clin Oncol. 21;28:511. Leleu X et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP
13 Champion-2 Study Design Carfilzomib 36, 45, or 56 mg/m 2 IV Days 1, 2, 8, 9, 15, 16 (2 mg/m 2 days 1, 2, cycle 1 only) Infusion duration: 3 minutes for all doses Cyclophosphamide 3 mg/m 2 oral Days 1, 8, 15 Dexamethasone 4 mg, oral or IV Days 1, 8, 15, day cycles 8 cycles, or progressive disease, unacceptable toxicity, or withdrawal of consent Boccia R et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-23. Champion-2 Best Overall Response and Time to Response 56 mg/m 2 dose cohort: ORR: 87.5% (95% CI, 61.7% 98.4%) Median time to response: 1 month (range, months) 36 mg/m 2 (N = 3) 45 mg/m 2 (N=3) 56 mg/m 2 (N=16) Best overall response, n (%) Stringent complete response Complete response Very good partial response Partial response Stable disease Progressive disease (.) (.) 1 (33.3) 1 (33.3) (.) 1 (33.3) (.) (.) 2 (66.7) 1 (33.3) (.) (.) (.) 1 (6.3) 7 (43.8) 6 (37.5) 2 (12.5) (.) Boccia R et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP
14 Transplant BMT CTN 72 Stem Cell Transplantation for Multiple Myeloma Incorporating Novel Agents: SCHEMA N=75 pts (25 in each arm) Lenalidomide maintenance Register and randomize MEL 2 mg/m 2 N=257 VRD 4* N=254 Lenalidomide maintenance MEL 2 mg/m 2 Lenalidomide maintenance *Bortezomib 1.3 mg/m 2 days 1, 4, 8,11 Lenalidomide 15 mg days 1 15 Dexamethasone 4 mg days 1, 8, 15 Every 21 days N=247 Lenalidomide 3 years : 1 mg/d for 3 cycles, then 15 mg/d Amendment in 214 changed Lenalidomide maintenance until disease progression after report of CALGB
15 Stamina: PFS 1 8 Probability, % month estimate and 95% CI Auto/Auto: 56.5 (49.4, 62.9) Auto/RVD: 56.7 (5., 62.8) Auto/Maint: 52.2 (45.4, 58.6) Stadtmauer EA et al. Blood. 216;128: Abstract LBA-1. Lenalidomide Maintenance: Meta-Analysis There is a 25% reduction in risk of death, representing an estimated 2.4-year increase in median survival (March 215 data cutoff) a Survival Probability Events/n LEN maint 215/65 Placebo/ Observation 275/63 Median OS (95% CI), mo HR (95% CI) P value NR (NR NR).75 (.63.9) ( ) 7-yr OS Overall Survival (Months) No. at Risk LEN maint Placebo/ Observation a Log-rank test and Cox model stratified by study to assess impact of lenalidomide maintenance on overall survival. Median for lenalidomide treatment arm was extrapolated to be 115 months based on median of the control arm and HR (median, 86 months; HR =.75). HR, hazard ratio; maint, maintenance; NR, not reached; OS, overall survival. Attal M et al. J Clin Oncol,. 216;34: Abstract 81. 5% 62% 15
16 Overall Survival: Subgroup Analysis LEN maint a Placebo/ Observation a HR (95% CI) < 6 y ( ) Age b 6 y ( ) Sex Male ( ) Female ( ) I/II ( ) ISS stage c III ( ) CR ( ) Response after ASCT (prior to maint) CR/VGPR (.54-.9) PR/SD d ( ) Normal LDH e ( ) > ULN ( ) Adverse-risk cytogenetics es ( ) at diagnosis f No ( ) < 5 ml/min CrCl at diagnosis g ( ) 5 ml/min ( ) < 5 ml/min ( ) CrCl after ASCT h 5 ml/min ( ) HR Favors LEN maint Favors placebo/ observation a Number of patients. b For CALGB and IFM, age at randomization is available/used. For GIMEMA, only age at diagnosis is available. c The ISS stage was based on β2 microglobulin and albumin at diagnosis for GIMEMA and IFM and at registration for the CALGB. d Four patients upon central review did not meet the criteria for SD. e LDH data were available only for IFM and GIMEMA. f Cytogenetic data were available only for IFM and GIMEMA. g The patients with missing CrCl at diagnosis data were in CALGB and IFM. h CrCl post-asct data were available only for CALGB and IFM. ASCT, autologous stem cell transplant; CR, complete response; CrCl, creatinine clearance; HR, hazard ratio; ISS, International Staging System; LDH, lactate dehydrogenase; LEN, lenalidomide; maint, maintenance; PR, partial response; SD, stable disease; ULN, upper limit of normal; VGPR, very good partial response. Attal M et al. J Clin Oncol,. 216;34: Abstract 81. Denosumab vs Zoledronic Acid HR (95% CI) =.98 (.85, 1.14); P=.1 (Noninferiority) Raje N et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP
17 Progression-Free Survival HR (95% CI) =.82 (.68,.99); P=.36 (Descriptive) Median duration (95% CI), months Denosumab (34.3, not estimable) Zoledronic acid (3.19, not estimable) Raje N et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-46. MRD in Myeloma 17
18 MRD Negativity: Daratumamab Results in Deeper Responses in Combinations with Revlimid or Velcade ITT population, % POLLUX CASTOR * * DRd Rd DRd Rd DRd Rd DVd Vd DVd Vd DVd Vd MRD negative MRD positive MRD negative MRD positive ITT population, % % of MRD-negative patients among those who achieved CR *P<.5; P<.5 Avet-Loiseau H et al. Blood. 216;128. Abstract 246. Relapsed Myeloma 18
19 ENDEAVOR: Study Design Randomization 1:1 N=929 Stratification: Prior proteasome inhibitor therapy Prior lines of treatment ISS stage Route of V administration Kd Carfilzomib* 56 mg/m 2 IV Days 1, 2, 8, 9, 15, 16 (2 mg/m 2 days 1, 2, cycle 1) Infusion duration: 3 minutes for all doses Dexamethasone 2 mg Days 1, 2, 8, 9, 15, 16, 22, day cycles until PD or unacceptable toxicity Vd Bortezomib 1.3 mg/m 2 (3 5 second IV bolus or subcutaneous injection) Days 1, 4, 8, 11 Dexamethasone 2 mg Days 1, 2, 4, 5, 8, 9, 11, day cycles until PD or unacceptable toxicity Treat to progression Treat to progression Primary end point: PFS by IRC Secondary end points: OS ORR DOR Grade 2 PN rate Safety * Carfilzomib was administered for 3 weeks out of 4 ISS, International Staging System; IV, intravenous; Kd, carfilzomib and dexamethasone; PD, progressive disease; Vd, bortezomib and dexamethasone; V, bortezomib. Siegel DS et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract PS-254. Primary End Point: Progression-Free Survival Proportion Surviving Without Progression Disease progression or death n (%) Median PFS months HR for Kd vs Vd (95% CI) Kd (n=464) 171 (37) (.44.65) 1-sided P<.1 Vd (n=465) 243 (52) Kd Vd Months Since Randomization Median follow-up: 11.2 months Siegel DS et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract PS
20 Overall Survival Proportion Surviving Kd Vd Death n (%) Median OS months HR for Kd vs Vd (95% CI) Kd (n=464) 189 (4.7) 47.6 Vd (n=465) 29 (44.9) ( ) 1-sided P= Months Number at risk: Kd Vd Siegel DS et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract PS-254. Pembrolizumab, Pomalidomide, Dexamethasone Characteristic N=48 Median lines of prior therapy (Range) >3 Prior therapy no. (%) ASCT Proteasome inhibitors Bortezomib Carfilzomib IMiDs Lenalidomide Refractory Proteasome inhibitors Lenalidomide Double-refractory to IMiDs and PI 3 (2-5) 13 (27%) 31 (72%) 48 (1%) 48 (1%) 24 (5%) 48 (1%) 48 (1%) 38 (79%) 43 (9%) 35 (73%) 2
21 Responses Response Category Evaluable Patients (N=45) Double refractory N=32 High risk cytogenetics N=27 Overall response no. (%) 29 (65) 22 (68) 15 (56) Best response no. (%) scr 3 (7) 1 (3) 2 (7) CR 1 (2) 1 (3) 1 (4) VGPR 9 (2) 6 (18) 1 (4) PR 16 (36) 14 (44) 11 (41) Isatuximab Pts received prophylaxis against infusion reactions prior to treatment* IARs reported in 9/2 pts (45%); all Gr 1/2 severity IARs occurred predominantly during the first infusion IAR after first infusion in three pts; one IAR after 18th infusion No treatment discontinuations due to IARs Initial infusion rate: 87.5 mg/h (5 mg/kg); 175 mg/h (1 and 2 mg/kg) Median infusion duration, hrs First infusion: 4.4 (1 mg/kg), 4.7 (2 mg/kg) Subsequent infusions: 2.6 (1 mg/kg), 4.6 (2 mg/kg) Patients (%) IARs by infusion and dose Grade 1 Grade 2 1 st >1 1 st >1 1 st >1 (n=8) (n=8) (n=6) (n=6) (n=6) (n=6) 5 mg/kg 1 mg/kg 2 mg/kg Isatuximab dose Data cut-off August 15, 216. *Diphenhydramine 5 mg IV (or equivalent), ranitidine 5 mg IV (or equivalent), and acetaminophen 65 1 mg orally Richardson P et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP
22 Response Summary 1 PR VGPR CR 8 ORR (%) % % 64.% QW/Q2W (n=8) 1 QW/Q2W (n=6) All patients (n=14) Among IMiD-refractory pts, the confirmed ORR was 64% (7/11) Three pts with high-risk cytogenetics (del17p or t[4:14]): one attained VGPR and another minimal response (MR) Data cut-off August 15, 216. a Efficacy data for the 2 mg/kg cohort are not yet mature. CR, complete response; ORR, overall response rate; PR, partial response; VGPR, very good partial response Richardson P et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-27. Baseline Demographics and Clinical Characteristics Characteristic DARA + POM-D N=13 Age, y Median (range) 64 (35-86) Cytogenetic profile, n (%)* Standard risk High risk del17p t(4;14) t(14;16) n=87 65 (75) 22 (25) 16 (18) 6 (7) 1 (1) DARA + POM-D Characteristic N=13 Prior lines of therapy, n (%) Median (range) 4 (1-13) >3 53 (52) Prior ASCT, n (%) 76 (74) Prior PI, n (%) Prior BORT Prior CARF 12 (99) 11 (98) 34 (33) Prior LEN, n (%) 13 (1) Prior PI + IMiD, n (%) 12 (99) Refractory to, n (%) LEN BORT CARF 92 (89) 73 (71) 31 (3) Refractory to PI + IMiD, n (%) 73 (71) ISS, International Staging System; ASCT, autologous stem cell transplant; PI, proteasome inhibitor; BORT, bortezomib; CARF, carfilzomib; LEN, lenalidomide; IMiD, immunomodulatory drug. *Based on FISH or karyotyping. Percentages based on n=87 as denominator. Chari A et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP
23 Responses ORR (scr+cr+vgpr+pr) Best response scr CR VGPR PR MR SD PD NE VGPR or better (scr+cr+vgpr) DARA + POM-D (N=13) n (%) 95% CI 62 (6) (8) 9 (9) 26 (25) 19 (18) 2 (2) 26 (25) 3(3) 1 (1) (42) CR or better (scr+cr) 17 (17) ORR, % % CR or better PR VGPR CR scr ORR = 6% DARA + POM-D (N = 13) 42% VGPR or better Deep responses were observed with DARA + POM-D Chari A et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-24. Venetoclax 23
24 BCL2 Proteins Regulate Cell Survival BCL2 Cellular Stress Examples include: Most Cancer Therapies Becoming Cancer Apoptosis (a mechanism by which cells die) BCL2 Proteins Regulate Cell Survival Venetoclax BCL2 Cellular Stress Examples include: Most Cancer Therapies Becoming Cancer Apoptosis (a mechanism by which cells die) 24
25 Types of Initial Therapy Percentage of patients (n=124) 36.8 (n=49) 29.9 (n=179) 42.6 (n=156) 39.8 (n=53) 48.2 (n=289) p= (n=26) 14.9 (n=54) (n=89) 8.2 (n=3) 3.8 (n=5) 7. (n=42). PI-based IMiD-based PI+IMiD-based Others t(11;14) Non-t(11;14) translocations No translocation Kumar S et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-45. Survival No translocation t(11;14) Non-t(11;14) translocation PFS, median (95% CI) P value OS, median (95% CI) P value No translocation (n=599) 28.3 ( ) 13.6 ( ) t(11;14) (n=366) 23. ( ) < ( ) <.1 Non-t(11;14) translocation (n=133) 19. ( ) 49.8 ( ) Kumar S et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP
26 Single-Agent Venetoclax 5 scr CR VGPR PR Percentage of Patients ORR 21% 3% 4% 8% 6% All Patients N=66 ORR 4% 4% 1% 13% 13% t(11;14) n=3 ORR 6% 3% 3% non-t(11;14) n=36 Data cutoff of 19Aug216 Kumar S et al. Presented at the 16 th International Myeloma Workshop, March 1-4, 217. Abstract OP-45. There Are Several BCL2 Proteins That Block Apoptosis Venetoclax Cellular Stress Examples include: Most Cancer Therapies Becoming Cancer MCL1 BCLX BCL2 A M G Apoptosis (a mechanism by which cells die) 26
27 New Immune Therapies New Immune Therapies in Myeloma CAR T-cells Bi-specifics Myeloma targets for both CAR T-cells and Bispecifics include: BCMA and SLAMF7 27
28 Questions & Answers Closing 28
29 Resources for ou! MMRF nurse specialist Have questions about the trials or information you heard today? Call our MMRF nurse specialists. An MMRF nurse specialist can guide you through your multiple myeloma journey every step of the way. Call Monday Friday, 9 7 ET Call now MMCT(6628) MMRF CoMMunity Gateway Accelerator Magazine Knowledge. Resources. Research. Community. Join our trusted multiple myeloma community! Continue the conversation with other patients, caregivers, and experts! Join today 29
30 Upcoming MMRF Webinars Summer 217 Series Topic Date Time Immunotherapy Meeting Highlights Monoclonal antibodies June 14, 217 1: PM ET Vaccines July 217 1: PM ET Engineered Immune Cells August 9, 217 1: PM ET American Society of Clinical Oncology and the European Hematology Association July 217 1: PM ET For more information or to register, visit: themmrf.org MMRF Multiple Myeloma Summits Fall 217 Saturday, September 16, 217 Chicago, Illinois Andrzej Jakubowiak, MD Chair University of Chicago Medical Center Saturday, October 14, 217 Charlotte, North Carolina Saad Z. Usmani, MD Chair Friday, November 3, 217 New ork City, New ork Sundar Jagannath, MD Chair The Mount Sinai Medical Center Tisch Cancer Institute Mount Sinai School of Medicine Levine Cancer Institute Saturday, November 18, 217 Los Angeles, California James Berenson, MD Co-Chair Institute for Myeloma and Bone Cancer Research Amrita. Krishnan, MD Co-Chair Judy and Bernard Briskin Center for Multiple Myeloma Research City of Hope Medical Center To register, please visit: themmrf.org/patient 3
COMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationDARA Monotherapy Studies
Usmani, SZ. Blood. 26. http://dx.doi.org/.82/blood-26-3-752. Lokhorst HM, et al. N Engl J Med. 25;373(3):27-29. Lonial S, et al. Lancet. 25. I DARA Monotherapy Studies Baseline Characteristics Median (range)
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationMultiple Myeloma Highlights: 2016 ASH Annual Meeting Patient Webinar
2016 ASH Annual Meeting Patient Webinar January 11, 2017 1 Welcome and Introductions Anne Quinn Young, MPH Vice President, Development and Strategic Partnerships Multiple Myeloma Research Foundation 2
More informationMULTIDISCIPLINARY MULTIPLE MYELOMA CARE
MULTIDISCIPLINARY MULTIPLE MYELOMA CARE Regional Lecture Series Leveraging a Multidisciplinary Approach to Multiple Myeloma Care Leveraging a Multidisciplinary Approach to Multiple Myeloma Care Abhinav
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationElotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationModified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
ORIGINAL ARTICLE 218 Oct 26. [Epub ahead of print] https://doi.org/1.394/kjim.218.144 Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
ClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Tomer Mark 1, Angelique Boyer 1, Adriana Rossi 1, Manan Shah 1, Roger Pearse 1, Faiza Zafar
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationCity of Hope, Duarte, CA, USA; 11 Columbia University Medical Center, New York, NY, USA. 1
Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With 2 Lines of Prior Therapy and Refractory or Relapsed and Refractory Multiple Myeloma
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationMultiple Myeloma New Trials and New Drugs. Rafat Abonour, M.D.
Multiple Myeloma New Trials and New Drugs Rafat Abonour, M.D. Treatment Combinations Then and Now NEW VD Rev/Dex CyBorD VTD VRD CDR SCT VD/VRD Lenalidomide Bortezomib Bortezomib Lenalidomide Thalidomide
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationRelapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationSTUDY DESIGN. VMP 6-week cycles, total of 9 cycles. Figure 2. Alcyone study design. Countries housing study sites are shaded in gold.
TPS8608 A Randomized Open-label Study of Bortezomib, Melphalan, And Prednisone (VMP) Versus Daratumumab () Plus VMP in Patients With Previously Untreated Multiple Myeloma (MM) Who Are Ineligible for High-dose
More informationTherapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz
Therapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz 15.6.218 Newly Diagnosed Multiple Myeloma Transplant Eligible NDMM TE VCD is preferable to
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationMultiple Myeloma. Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario
Multiple Myeloma Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario Disclosures Relationships with financial sponsors: Grants/Research Support: n/a Speakers Bureau/Honoraria:
More informationOvercoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma
Overcoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma George Somlo M.D. City of Hope Comprehensive Cancer Center The Cause 1 Myeloma: Clinical Features Bone
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationThe TOURMALINE-MM1 study: results and expert insights
The TOURMALINE-MM1 study: results and expert insights Professor Faith Davies UAMS Myeloma Institute, Arkansas, USA This educational meeting was organised and fully funded by Takeda UK Ltd. Takeda medicines
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More information2015 Updates in Multiple Myeloma
2015 Updates in Multiple Myeloma Siddhartha Ganguly, MD, FACP Professor of Medicine Director, Lymphoma and Myeloma Blood and Marrow Transplantation Program The University of Kansas Medical Center 1 Earliest
More information